TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$4.40 USD
+0.23 (5.52%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $4.32 -0.08 (-1.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.40 USD
+0.23 (5.52%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $4.32 -0.08 (-1.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Sanofi (SNY) Q1 Earnings, Sales Grow on Coronavirus-Led Buying
by Zacks Equity Research
Sanofi (SNY) beats estimates for both earnings and sales. Around half of the sales and earnings growth at CER was due to COVID-19 associated patient stockpiling. Stock down.
Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus
by Zacks Equity Research
Sanofi (SNY) partners with Luminostics to make a COVID-19 smartphone-based self-testing solution, which will be based on the latter's proprietary technology.
Moderna Rallies on US Government Grant for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.
Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.
Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.
Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus
by Ekta Bagri
Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
J&J Plans to Initiate Coronavirus Vaccine Study in September
by Zacks Equity Research
J&J (JNJ) announces its plan to start an early-stage clinical study on its selected vaccine candidate in September. The company also expands agreement with BARDA to accelerate vaccine development.
Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine
by Zacks Equity Research
Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.
Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Translate Bio, Inc. (TBIO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -33.33% and 27.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Translate Bio, Inc. (TBIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Translate Bio, Inc. (TBIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of 8.89% and -28.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Translate Bio, Inc. (TBIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -26.67% and -32.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.
IPOs Are Heating Up Once Again
by Benjamin Rains
A few big-name companies have grabbed the lion's share of the IPO limelight so far this year, including major tech players Spotify (SPOT) and Dropbox (DBX). Meanwhile, some investors might have missed just how busy 2018 has been, in fact, June could end up being the busiest month of initial public offerings in three years.